Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 214

1.

Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.

van den Berg MJ, van der Graaf Y, de Borst GJ, Kappelle LJ, Nathoe HM, Visseren FL; SMART Study Group.

Am J Cardiol. 2016 Jun 28. pii: S0002-9149(16)31119-5. doi: 10.1016/j.amjcard.2016.06.048. [Epub ahead of print]

PMID:
27471056
2.

Metabolic consequences of adipose tissue dysfunction and not adiposity per se increase the risk of cardiovascular events and mortality in patients with type 2 diabetes.

Franssens BT, Westerink J, van der Graaf Y, Nathoe HM, Visseren FL; SMART study group.

Int J Cardiol. 2016 Jul 5;222:72-77. doi: 10.1016/j.ijcard.2016.07.081. [Epub ahead of print]

PMID:
27458826
3.

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease.

Bots SH, van der Graaf Y, Nathoe HM, de Borst GJ, Kappelle JL, Visseren FL, Westerink J; SMART Study Group.

Cardiovasc Diabetol. 2016 Jul 19;15(1):101. doi: 10.1186/s12933-016-0418-1.

4.

Wideband Doppler Ultrasound-guided Mini-endoscopic Combined Intrarenal Surgery as an Effective and Safe Procedure for Management of Large Renal Stones: A Preliminary Report.

Inoue T, Kinoshita H, Okada S, Hamamoto S, Taguchi M, Murota T, Matsuda T; SMART Study Group.

Urology. 2016 May 25. pii: S0090-4295(16)30239-4. doi: 10.1016/j.urology.2016.05.038. [Epub ahead of print]

PMID:
27235750
5.

HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes.

Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Care. 2016 Aug;39(8):1424-30. doi: 10.2337/dc16-0155. Epub 2016 May 23.

PMID:
27222511
6.

The relation between apolipoprotein E (APOE) genotype and peripheral artery disease in patients at high risk for cardiovascular disease.

Koopal C, Geerlings MI, Muller M, de Borst GJ, Algra A, van der Graaf Y, Visseren FL; SMART Study Group.

Atherosclerosis. 2016 Mar;246:187-92. doi: 10.1016/j.atherosclerosis.2016.01.009. Epub 2016 Jan 11.

PMID:
26800308
7.

Association of High Ankle Brachial Index With Incident Cardiovascular Disease and Mortality in a High-Risk Population.

Hendriks EJ, Westerink J, de Jong PA, de Borst GJ, Nathoe HM, Mali WP, van der Graaf Y, van der Schouw YT, Beulens JW; SMART Study Group.

Arterioscler Thromb Vasc Biol. 2016 Feb;36(2):412-7. doi: 10.1161/ATVBAHA.115.306657. Epub 2015 Dec 29.

PMID:
26715681
8.

Hypertensive Target Organ Damage and Longitudinal Changes in Brain Structure and Function: The Second Manifestations of Arterial Disease-Magnetic Resonance Study.

van der Veen PH, Geerlings MI, Visseren FL, Nathoe HM, Mali WP, van der Graaf Y, Muller M; SMART Study Group.

Hypertension. 2015 Dec;66(6):1152-8. doi: 10.1161/HYPERTENSIONAHA.115.06268. Epub 2015 Oct 26.

PMID:
26503971
9.

The relation between the presence of cardiovascular disease and vascular risk factors in offspring and the occurrence of new vascular events in their parents already at high vascular risk.

Weijmans M, van der Graaf Y, de Borst GJ, Asselbergs FW, Cramer MJ, Algra A, Visseren FL; SMART study group.

Am Heart J. 2015 Oct;170(4):744-752.e2. doi: 10.1016/j.ahj.2015.06.023. Epub 2015 Jul 3.

PMID:
26386798
10.

Cerebellar Cortical Infarct Cavities: Correlation With Risk Factors and MRI Markers of Cerebrovascular Disease.

De Cocker LJ, Kloppenborg RP, van der Graaf Y, Luijten PR, Hendrikse J, Geerlings MI; SMART Study Group.

Stroke. 2015 Nov;46(11):3154-60. doi: 10.1161/STROKEAHA.115.010093. Epub 2015 Sep 17. Erratum in: Stroke. 2016 Feb;47(2):e38.

PMID:
26382175
11.

Completeness of the circle of Willis and risk of ischemic stroke in patients without cerebrovascular disease.

van Seeters T, Hendrikse J, Biessels GJ, Velthuis BK, Mali WP, Kappelle LJ, van der Graaf Y; SMART Study Group.

Neuroradiology. 2015 Dec;57(12):1247-51. doi: 10.1007/s00234-015-1589-2. Epub 2015 Sep 10.

12.

Association between CETP gene polymorphism, insulin resistance and risk of diabetes mellitus in patients with vascular disease.

Koopal C, van der Graaf Y, Asselbergs FW, Westerink J, Visseren FL; SMART study group.

Atherosclerosis. 2015 Oct;242(2):605-10. doi: 10.1016/j.atherosclerosis.2015.08.015. Epub 2015 Aug 13.

PMID:
26318399
13.

Body weight, metabolic dysfunction, and risk of type 2 diabetes in patients at high risk for cardiovascular events or with manifest cardiovascular disease: a cohort study.

Franssens BT, van der Graaf Y, Kappelle LJ, Westerink J, de Borst GJ, Cramer MJ, Visseren FL; SMART Study Group.

Diabetes Care. 2015 Oct;38(10):1945-51. doi: 10.2337/dc15-0684. Epub 2015 Aug 25.

PMID:
26307608
14.

The relation between HbA1c and cardiovascular events in patients with type 2 diabetes with and without vascular disease.

Kranenburg G, van der Graaf Y, van der Leeuw J, Nathoe HM, de Borst GJ, Kappelle LJ, Visseren FL, Westerink J; SMART Study Group.

Diabetes Care. 2015 Oct;38(10):1930-6. doi: 10.2337/dc15-0493. Epub 2015 Aug 25.

PMID:
26307606
15.

A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.

O'Connor JL, Gardner EM, Esser S, Mannheimer SB, Lifson AR, Telzak EE, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

HIV Med. 2016 Feb;17(2):124-32. doi: 10.1111/hiv.12284. Epub 2015 Jul 17.

PMID:
26186609
16.

Relationship between recurrent miscarriage and early preterm delivery and recurrent events in patients with manifest vascular disease: The SMART study.

Heida KY, Koster MP, Franx A, Veerbeek JH, Westerink J, Bots ML, Spiering W; SMART Study Group.

Eur J Prev Cardiol. 2016 Mar;23(5):486-92. doi: 10.1177/2047487315594085. Epub 2015 Jun 30.

PMID:
26130496
17.

Cerebellar infarct patterns: The SMART-Medea study.

De Cocker LJ, Geerlings MI, Hartkamp NS, Grool AM, Mali WP, Van der Graaf Y, Kloppenborg RP, Hendrikse J; SMART study group.

Neuroimage Clin. 2015 Feb 9;8:314-21. doi: 10.1016/j.nicl.2015.02.001. eCollection 2015.

18.

Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.

Bayas A, Ouallet JC, Kallmann B, Hupperts R, Fulda U, Marhardt K; SMART study group.

Expert Opin Drug Deliv. 2015 Aug;12(8):1239-50. doi: 10.1517/17425247.2015.1057567. Epub 2015 Jun 22.

PMID:
26098143
19.

Prevalence and risk of cardiovascular risk factors and events in offspring of patients at high vascular risk and effect of location of parental vascular disease.

Weijmans M, van der Graaf Y, de Borst GJ, Asselbergs FW, Cramer MJ, Algra A, Visseren FL; SMART study group.

Int J Cardiol. 2015 Sep 15;195:195-202. doi: 10.1016/j.ijcard.2015.05.059. Epub 2015 May 21.

PMID:
26046422
20.

Effect of Type 2 Diabetes on Recurrent Major Cardiovascular Events for Patients With Symptomatic Vascular Disease at Different Locations.

Stam-Slob MC, van der Graaf Y, de Borst GJ, Cramer MJ, Kappelle LJ, Westerink J, Visseren FL; SMART Study Group.

Diabetes Care. 2015 Aug;38(8):1528-35. doi: 10.2337/dc14-2900. Epub 2015 Jun 2.

PMID:
26038582
Items per page

Supplemental Content

Loading ...
Write to the Help Desk